Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
LAMC2 regulated by microRNA-125a-5p accelerates the progression of ovarian cancer via activating p38 MAPK signalling.
|
31301414 |
2019 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Linc00161 regulated the drug resistance of ovarian cancer via modulating microRNA-128/MAPK1.
|
30556928 |
2019 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we systematically evaluated the extent of MEK/ERK pathway activation and efficacy of pathway inhibition in a large panel of well-annotated HGSOC patient-derived xenograft models.
|
30679390 |
2019 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
FAK-ERK activation in cell/matrix adhesion induced by the loss of apolipoprotein E stimulates the malignant progression of ovarian cancer.
|
29458390 |
2018 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
MEK inhibitor U0126 inhibits basal and chemodrug-induced phosphorylation of ERK as well as Mnk1 and eIF4E, suggesting that Mnk1/eIF4E are the downstream signaling of ERK pathway and chemotherapy agents activate ERK/MNK/eIF4E in a MEK-dependent manner. eIF4E overexpression promotes ovarian cancer cell growth without affecting migration.
|
28766096 |
2018 |
Malignant neoplasm of ovary
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Cisplatin induced apoptosis of ovarian cancer A2780s cells by activation of ERK/p53/PUMA signals.
|
28287251 |
2018 |
Malignant neoplasm of ovary
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
CAF: cancer-associated fibroblasts; COG: Cluster of Orthologous Groups; DEA: disease enrichment analysis; EOC: epithelial ovarian carcinoma; ESCC: oesophageal squamous cell carcinoma; GSI: gamma secretase inhibitor; GO: Gene Ontology; GSEA: gene set enrichment analyzes; HAS: Hungarian Academy of Sciences; lncRNAs: long non-coding RNAs; MAPK/ERK: mitogen-activated protein kinase/extracellular signal-regulated kinases; NGS: next-generation sequencing; ncRNAs: non-coding RNAs; OvC: ovarian cancer; PI3K/Akt/mTOR: phosphatidylinositol-3-kinase/protein kinase B/mammalian target of rapamycin; RT-PCR: real-time polymerase chain reaction; SNP: single nucleotide polymorphism; TF: transcription factor; TGF-β: transforming growth factor-β.
|
28574782 |
2017 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways.
|
28440503 |
2017 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results suggest that the C-terminus of IGFBP-5 exerts anti-cancer activity by inhibiting angiogenesis via regulation of the Akt/ERK and NF-kB-VEGF/MMP-9 signaling pathway, and might be considered as a novel angiogenesis inhibitor for the treatment of ovarian cancer.
|
28008951 |
2016 |
Malignant neoplasm of ovary
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
As paralogous gene mutations co‑occur frequently in human malignancies, we analyzed here a total of 263 ovarian carcinomas for the presence of MAPK1 and paralogous MAPK3 mutations by DNA sequencing.
|
26548627 |
2016 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
TGF-β1 contributes to CD8+ Treg induction through p38 MAPK signaling in ovarian cancer microenvironment.
|
27322208 |
2016 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
HOTAIR Interacting with MAPK1 Regulates Ovarian Cancer skov3 Cell Proliferation, Migration, and Invasion.
|
26117268 |
2015 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
MicroRNA-497 suppresses angiogenesis by targeting vascular endothelial growth factor A through the PI3K/AKT and MAPK/ERK pathways in ovarian cancer.
|
25176450 |
2014 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, bortezomib may induce ERK phosphorylation to suppress cathepsin B and inhibit the catalytic process of autophagy in ovarian cancer and other solid tumors.
|
25375375 |
2014 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Additionally, RAS/RAF/MEK/ERK pathway-targeted therapy may benefit selected patients with type II ovarian carcinoma harboring KRAS/MAPK1 amplifications.
|
23820584 |
2013 |
Malignant neoplasm of ovary
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Using human OC cell lines and tissues microarrays of human OC biopsies, we assessed the mechanism by which OC ascites increase Mcl-1 expression using Western blots, chemical inhibitors of ERK and small-inhibitory RNA treatments.
|
23158473 |
2012 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer.
|
21057220 |
2011 |
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
CTD_human |
We conclude that paclitaxel transiently transactivates EGFR, leading to activation of cell survival factors, such as ERK and AKT, and expression of survivin, which are all inclusively accountable for ovarian cancer cell resistance to paclitaxel treatment.
|
16211241 |
2005 |